The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

Trial Details
Trial status:
Recruitment start date:
Cancer Research UK
Chief Investigator:
Dr Rob Glynne–Jones
Recruitment target:
EudraCT number:
Contact details:
Lay summary:
A phase II Multicentre Open-label Randomised Study of Neoadjuvant Chemotherapy and Bevacizumab in Patients with MRI defined High-Risk Cancer of the Rectum
Design: A Phase II, Multicentre, Open-label, Randomised Study of Neoadjuvant Chemotherapy and Bevacizumab in Patients with MRI defined High-Risk Cancer of the Rectum.
Treatment: Patients will be randomised to receive FOLFOX + bevacizumab (Arm A) or FOLFOXIRI + bevacizumab (Arm B).  Treatment is given every 2 weeks for 12 weeks (6 cycles). Bevacizumab should be given for cycles 1 – 5 only.  Patients deemed suitable following PET/CT scan will undergo surgical resection, a minimum of 6 weeks after 
Key inclusion/exclusion criteria:
Patients must have histologically confirmed diagnosis of adenocarcinoma of the rectum. MRI-evaluated locally advanced tumour with the following:

- T3 tumours extending ≥4mm beyong the muscularis propria N0–N2
- Or tumours involving or threatening the peritoneal surface
- OR presence of macroscopic extramural venous invasion (V2 disease)
- AND for tumours below the peritoneal reflection, the primary tumour or involved lymph node (on MRI) must be >1 mm from the mesorectal fascia. 

The distal part of the tumour must be within 4-12 cm of the anal verge, and no evidence of established distant metastases.

Duration of recruitment: Recruitment is now closed.
The overall aim is to evaluate the efficacy and toxicity and feasibility of FOLFOX + bevacizumab and FOLFOXIRI + bevacizumab neoadjuvant therapy in poor prognosis rectal cancer as defined by MRI.
Trial protocols
Trial protocols must not be applied to patients treated outside trials. UCL CTC can only ensure that approved trial investigators are provided with amendments to protocols.
No protocols have been currently made available for download
Trial documents
No documents have been currently made available for download
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road

View map
+44 (0)20 7679 9898 (General CTC Enquiries)
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us